OOIR: Observatory of International Research

Papers

(The median citation count of Translational Neurodegeneration is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer’s disease mouse model	339
Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington’s disease mice	307
N6-methyladenosine-modified circRIMS2 mediates synaptic and memory impairments by activating GluN2B ubiquitination in Alzheimer's disease	191
Retraction Note: Alpha-synuclein overexpression in the olfactory bulb initiates prodromal symptoms and pathology of Parkinson’s disease	176
Life and disease status of patients with Parkinson’s disease during and after zero-COVID in China: an online survey	149
Retraction Note: Asiaticoside, a trisaccaride triterpene induces biochemical and molecular variations in brain of mice with parkinsonism	130
CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer’s disease	111
The C. elegans gba-3 gene encodes a glucocerebrosidase that exacerbates α-synuclein-mediated impairments in deletion mutants	98
NLRP3 inflammasome in cognitive impairment and pharmacological properties of its inhibitors	95
Impaired dynamic interaction of axonal endoplasmic reticulum and ribosomes contributes to defective stimulus–response in spinal muscular atrophy	93
Gene therapy breakthroughs in ALS: a beacon of hope for 20% of ALS patients	92
Patient-derived iPSC models of Friedreich ataxia: a new frontier for understanding disease mechanisms and therapeutic application	89
Oligodendrocyte progenitor cells in Alzheimer’s disease: from physiology to pathology	83
Impaired glymphatic function in the early stages of disease in a TDP-43 mouse model of amyotrophic lateral sclerosis	81
Role of dopamine in the pathophysiology of Parkinson’s disease	79
A novel plasma p-tau181 assay as a specific biomarker of tau pathology in Alzheimer's disease	71
Correction: A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau	69
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease	69
Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer’s disease: a comprehensive review of the characteristics and therapeutic strategies	67
Defective mitophagy and the etiopathogenesis of Alzheimer’s disease	65
Correction: Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease	65
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies	65
Cognitive dysfunction of patients infected with SARS-CoV-2 omicron variant in Shanghai, China	63
Hybrid nanostructures for neurodegenerative disease theranostics: the art in the combination of biomembrane and non-biomembrane nanostructures	63
Inflammasomes in neurodegenerative diseases	61

Remodeling of astrocyte secretome in amyotrophic lateral sclerosis: uncovering novel targets to combat astrocyte-mediated toxicity	61
ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein	58
Targeted delivery of BACE1 siRNA for synergistic treatment of Alzheimer's disease	57
Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside	56
Nose-to-brain drug delivery: from bench to bedside	53
Peripheral proteinopathy in neurodegenerative diseases	52
α-Synuclein oligomers potentiate neuroinflammatory NF-κB activity and induce Cav3.2 calcium signaling in astrocytes	51
Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology	51
Longitudinal evolution of cortical thickness signature reflecting Lewy body dementia in isolated REM sleep behavior disorder: a prospective cohort study	48
The emerging role of furin in neurodegenerative and neuropsychiatric diseases	48
Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson’s and Alzheimer’s disease	47
Microstructural integrity of the locus coeruleus and its tracts reflect noradrenergic degeneration in Alzheimer’s disease and Parkinson’s disease	45
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter	45
Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease	45
Multidimensional biomarkers for multiple system atrophy: an update and future directions	44
Astrocytes contribute to toll-like receptor 2-mediated neurodegeneration and alpha-synuclein pathology in a human midbrain Parkinson’s model	44
Improving vulnerable Calbindin1− neurons in the ventral hippocampus rescues tau-induced impairment of episodic memory	44
An AARS1 variant identified to cause adult-onset leukoencephalopathy with neuroaxonal spheroids and pigmented glia	43
Perivascular spaces relate to the course and cognition of Huntington’s disease	43
Aging-dependent YAP1 reduction contributes to AD pathology by upregulating the Nr4a1-AKT/GSK-3β axis	42
Genetic spectrum and clinical features in a cohort of Chinese patients with autosomal recessive cerebellar ataxias	41
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system	41
Neuronal and synaptic adaptations underlying the benefits of deep brain stimulation for Parkinson's disease	40
Targeting galectin-3 to counteract spike-phase uncoupling of fast-spiking interneurons to gamma oscillations in Alzheimer’s disease	38
Cerebrospinal fluid cyclase-associated protein 2 is increased in Alzheimer’s disease and correlates with tau pathology	38
Role of extracellular vesicle-carried ncRNAs in the interactive ‘dialogue’ within the brain and beyond: emerging theranostic epigenetic modifiers in brain-derived nanoplatforms	36
TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis	36
Ultrasensitive detection of aggregated α-synuclein using quiescent seed amplification assay for the diagnosis of Parkinson’s disease	36
Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease	35
Deficient AMPK-SENP1-Sirt3 signaling impairs mitochondrial complex I function in Parkinson’s disease model	35
Axonal tau reduction ameliorates tau and amyloid pathology in a mouse model of Alzheimer’s disease	34
Effects of transcranial ultrasound stimulation pulsed at 40 Hz on Aβ plaques and brain rhythms in 5×FAD mice	34
Metabolic regulation of microglial phagocytosis: Implications for Alzheimer's disease therapeutics	32
Emerging role of senescent microglia in brain aging-related neurodegenerative diseases	32
In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use	32
Extracellular PHF-tau modulates astrocyte mitochondrial dynamics and mediates neuronal connectivity	32
Plasma proteomic signatures as predictors of dementia risk in individuals with sleep apnea: a cohort study	32
Nootropic foods in neurodegenerative diseases: mechanisms, challenges, and future	31
Alterations in sleep-activity cycles and clock gene expression across the synucleinopathy spectrum	31
Biases in α-synuclein immuno-quantitation: a core problem for basic and ancillary studies of Parkinson’s disease and multiple system atrophy	29
Deciphering lipid dysregulation in ALS: from mechanisms to translational medicine	28
Retrotransposon: an insight into neurological disorders from perspectives of neurodevelopment and aging	28
Stress granules: emerging players in neurodegenerative diseases	28
Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration	28
Linking APOE4/4 genotype to microglial lipid droplets and neurotoxicity in Alzheimer’s disease	28
Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model	28
Pathophysiological subtypes of mild cognitive impairment due to Alzheimer’s disease identified by CSF proteomics	28
Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease	27
Correction: CD2AP deficiency aggravates Alzheimer’s disease phenotypes and pathology through p38 MAPK activation	26
Myelin repair in Alzheimer’s disease: a review of biological pathways and potential therapeutics	25

Astrocyte dysfunction in Parkinson's disease: from the perspectives of transmitted α-synuclein and genetic modulation	25
Pathological insights from amyotrophic lateral sclerosis animal models: comparisons, limitations, and challenges	25
Intestine-derived α-synuclein initiates and aggravates pathogenesis of Parkinson’s disease in Drosophila	25
Increased cysteinyl-tRNA synthetase drives neuroinflammation in Alzheimer’s disease	25
TLR2 and TLR4 in Parkinson’s disease pathogenesis: the environment takes a toll on the gut	24
Endosomal traffic disorders: a driving force behind neurodegenerative diseases	24
CSF biomarkers of reactive glial cells are associated with blood–brain barrier leakage and white matter lesions	24
DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson’s disease	24
TRPV1 alleviates APOE4-dependent microglial antigen presentation and T cell infiltration in Alzheimer's disease	23
Argyrophilic grain disease is common in older adults and may be a risk factor for suicide: a study of Japanese forensic autopsy cases	22
GCN2 inhibition reduces mutant SOD1 clustering and toxicity and delays disease progression in an amyotrophic lateral sclerosis mouse model	21
Correction: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia	21
Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington’s disease	20
Brain metabolism in Alzheimer’s disease: biological mechanisms of exercise	20
Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease	19
Glutathione oxidation in cerebrospinal fluid as a biomarker of oxidative stress in amyotrophic lateral sclerosis	19
Alleviating the unwanted effects of oxidative stress on Aβ clearance: a review of related concepts and strategies for the development of computational modelling	19
Correction to: Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies	19
N-terminus α-synuclein detection reveals new and more diverse aggregate morphologies in multiple system atrophy and Parkinson’s disease	19
Targeting the glymphatic system: Aβ accumulation and phototherapy strategies across different stages of Alzheimer’s disease	18
Critical role of ROCK1 in AD pathogenesis via controlling lysosomal biogenesis and acidification	18
Genetic heterogeneity on sleep disorders in Parkinson’s disease: a systematic review and meta-analysis	18
APOE ε4-dependent effects on the early amyloid pathology in induced neurons of patients with Alzheimer’s disease	18
CRISPR base editing-mediated correction of a tau mutation rescues cognitive decline in a mouse model of tauopathy	18
Research progress on the role of extracellular vesicles in neurodegenerative diseases	17
Transcranial alternating current stimulation (tACS) at gamma frequency: an up-and-coming tool to modify the progression of Alzheimer’s Disease	16
Toward a biomarker panel measured in CNS-originating extracellular vesicles for improved differential diagnosis of Parkinson’s disease and multiple system atrophy	16
RNA targets of TDP-43: Which one is more important in neurodegeneration?	16
Long-term exercise enhances meningeal lymphatic vessel plasticity and drainage in a mouse model of Alzheimer's disease	16
N-terminally truncated Aβ4-x proteoforms and their relevance for Alzheimer’s pathophysiology	16
Optogenetic induction of TDP-43 aggregation impairs neuronal integrity and behavior in Caenorhabditis elegans	15
The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases	15
α-Synuclein arginylation in the human brain	15
Blockage of VEGF function by bevacizumab alleviates early-stage cerebrovascular dysfunction and improves cognitive function in a mouse model of Alzheimer’s disease	15
Putative novel CSF biomarkers of Alzheimer’s disease based on the novel concept of generic protein misfolding and proteotoxicity: the PRAMA cohort	15
Translational Neurodegeneration in the era of fast growing international brain research	15
Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases	15
Stepping up to meet the challenge of freezing of gait in Parkinson’s disease	14
Employing nanoparticle tracking analysis of salivary neuronal exosomes for early detection of neurodegenerative diseases	14
Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease	14
Inflammasome activation under high cholesterol load triggers a protective microglial phenotype while promoting neuronal pyroptosis	14
Chronic subthalamic nucleus deep brain stimulation reduces pathological TrkB aggregates in a Parkinson’s disease rat model	13
Updates in Alzheimer's disease: from basic research to diagnosis and therapies	13
Cyclooxygenase-1 deletion in 5 × FAD mice protects against microglia-induced neuroinflammation and mitigates cognitive impairment	13
Neddylation-dependent protein degradation is a nexus between synaptic insulin resistance, neuroinflammation and Alzheimer’s disease	13
LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease	13
SARS-CoV-2 membrane protein induces neurodegeneration via affecting Golgi-mitochondria interaction	13
Propagation of tau and α-synuclein in the brain: therapeutic potential of the glymphatic system	13
Dietary fasting and time-restricted eating in Huntington’s disease: therapeutic potential and underlying mechanisms	13